Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of FT011 in diffuse systemic sclerosis
2020-005116-21Phase 2Completed
- Sponsor
- Certa Therapeutics
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of asengeprast in systemic sclerosis (SSc) (3 arms), sponsored by Certa Therapeutics. Primary endpoints: FT011 cmax after single dose and after 12 weeks, FT011 tmax after single dose and after 12 weeks and 1 more. Started Jun 2021; status: completed.
02
Drugs
asengeprast
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2020-005116-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005116-21.